Therapeutic milestones, a gene-therapy readout and laboratory imaging tools

1. FDA approves tiratricol for peripheral effects of MCT8 deficiency¹

The FDA approved Emcitate, a tiratricol oral suspension, for peripheral thyrotoxicosis in patients with MCT8 deficiency on 28 September. The agency describes it as the first approved treatment for symptoms of the rare genetic disorder. Its assessment drew on a randomised placebo-controlled study and longer-term open-label evidence showing reduced excess blood thyroid hormone and improvements in related cardiovascular and metabolic symptoms. For researchers, the milestone illustrates a transporter-bypassing pharmacological strategy. The announcement concerns peripheral thyroid-hormone effects; it should not be read as proof that the treatment reverses the disorder’s neurological damage.¹

2. Huntington gene-therapy update exposes uncertainty at four years²

uniQure announced additional AMT-130 gene-therapy results on 29 September, extending its Huntington’s disease analysis to four years. Among 12 high-dose patients, the primary composite disease-rating endpoint showed a reported 44% slowing against an external natural-history control, but was not statistically significant (p=0.144). Functional capacity showed a nominally significant difference. The company reported 53% missing follow-up data in the updated external control at four years and attributed part of the uncertainty to attrition. This is a consequential new readout for development of a disease-modifying therapy; these externally controlled results do not establish randomized comparative efficacy.²

3. BARDA contract funds the next antifungal development stage³

SCYNEXIS disclosed a BARDA contract signed on 25 September and announced on 28 September to develop SCY-247, its second-generation fungerp antifungal candidate. The initial base period provides approximately $18.5 million for oral and intravenous development toward a Phase 2 invasive-candidiasis study. Total potential support is up to $214 million, with the balance depending on BARDA exercising as many as six options over a possible ten-year term. The cost-sharing agreement creates a concrete development pathway for treatment and prevention research; the headline ceiling is contingent funding, and the contract does not establish clinical efficacy.³

4. Logic-gated CAR-T enters clinical dosing with expanded financing⁴

Link Cell Therapies announced that clinical dosing has begun for LNK001 in a Phase 1 study of advanced or metastatic clear-cell renal cancer at MD Anderson. The investigational CAR-T therapy requires co-expression of CAIX and ENPP3, a design intended to limit the off-tumour toxicity that has constrained single-antigen CAIX targeting. The company also expanded its Series A from $60 million to $90 million to support additional programmes, including planned colorectal-cancer development. This is a tangible transition from targeting logic to clinical testing; the announcement reports no established patient efficacy or safety advantage.⁴

5. Agilent adds AI cell segmentation to BioTek imaging workflows⁵

Agilent announced the BioTek Gen5 AI cell identification module on 29 September, adding AI-based segmentation to compatible Cytation and Lionheart automated imagers. The software supports label-free and fluorescence imaging, including live-cell and kinetic assays, within existing Gen5 workflows. Agilent says the module reduces conventional threshold-setting and parameter-tuning steps for supported cell-counting and confluence analyses. For laboratories using these instruments, the launch offers a concrete route to automate part of image analysis in biological and drug-discovery experiments. The announcement describes vendor capabilities and intended workflow benefits; it does not provide an independent comparative accuracy benchmark.⁵